Esperion Therapeutics ESPR Number of Exercisable Options
Number of Exercisable Options at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's number of exercisable options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's number of exercisable options?
- Esperion Therapeutics (ESPR) reported number of exercisable options of 3.8M in Q1 2026.
- How has Esperion Therapeutics's number of exercisable options changed year-over-year?
- Esperion Therapeutics's number of exercisable options increased by 34.0% year-over-year, from 2.8M to 3.8M.
- What is the long-term trend for Esperion Therapeutics's number of exercisable options?
- Over 5 years (2020 to 2025), Esperion Therapeutics's number of exercisable options has grown at a 0.8% compound annual growth rate (CAGR), from 3.4M to 3.5M.
- What does number of exercisable options mean?
- The number of share-based payment options that have met all vesting requirements and are currently eligible for exercise by the holders. This represents the portion of the equity incentive pool that could be converted into common stock immediately. It is a critical component for calculating fully diluted share counts.